Botox® has been the default neuromodulator in North America for two decades, and it still is. But it no longer has the category to itself. Several FDA-approved botulinum toxin brands now compete directly with it, and a much larger set of non-toxin treatments compete for the same patient budget without containing any toxin at all.
This guide is the market view: who makes Botox, who its competitors are, what each is actually approved for, whether a generic or biosimilar Botox exists, and which non-toxin categories are pulling revenue away from injectables. If you want the clinical head-to-head — dosing ratios, onset, diffusion, protein load — that lives in our dedicated Botox vs. Xeomin vs. Dysport comparison. This page covers the landscape those products sit in.
Who Makes Botox?
Botox is manufactured by Allergan, which has been part of AbbVie since AbbVie’s acquisition of Allergan closed in 2020. The product is sold in two labeled forms — Botox Cosmetic for aesthetic indications and Botox for therapeutic ones — both containing the same active ingredient, onabotulinumtoxinA.
Botox occupies an unusual competitive position. It was first, it has by far the widest set of FDA-approved indications, and its brand name became the generic term for the entire category, which is a marketing asset competitors cannot buy. Patients ask for “Botox” the way they ask for a Band-Aid. That linguistic default is worth as much as any clinical advantage.
The Direct Competitors: FDA-Approved Botulinum Toxin Brands
These are the products that compete with Botox on the same mechanism. All are botulinum toxin. All work by blocking acetylcholine release at the neuromuscular junction. They differ in formulation, manufacturer, approved indications, storage, and unit definition.
Dysport (abobotulinumtoxinA)
Manufactured by Ipsen and distributed for aesthetic use in the United States by Galderma. Dysport is Botox’s oldest and most established competitor, with both cosmetic and therapeutic approvals including glabellar lines, cervical dystonia, and limb spasticity in adults and children.
Its distinguishing formulation trait is that it contains lactose and cow’s milk protein, which is a genuine screening consideration for patients with a milk protein allergy. Its units are defined against Ipsen’s own assay and are not equivalent to Botox units.
Xeomin (incobotulinumtoxinA)
Manufactured by Merz Aesthetics. Xeomin’s pitch is its purity: it is the “naked” toxin, stripped of the accessory complexing proteins that surround the active molecule in Botox, Dysport, and Jeuveau. Those proteins do nothing therapeutically, and the theoretical argument is that removing them lowers the antigenic load and therefore the odds of a patient developing neutralizing antibodies over years of repeat treatment.
Its more practical advantage is unglamorous and real: unopened Xeomin does not require refrigeration, which removes a cold-chain burden for practices. It carries both cosmetic and therapeutic approvals, including sialorrhea and spasticity.
Jeuveau (prabotulinumtoxinA)
Marketed by Evolus and manufactured in South Korea by Daewoong. Jeuveau is the category’s pure-play cosmetic product — it holds a single FDA approval, for glabellar lines, and has no therapeutic indications at all. That is a deliberate strategy, not a shortcoming: skipping the therapeutic development pathway is cheaper, and Evolus passes some of that through as a lower price point and aggressive aesthetic-first branding, including the “Newtox” positioning aimed at younger patients.
Its units are generally treated as roughly 1:1 with Botox, which makes it the easiest product in the class to substitute directly — a meaningful part of its commercial appeal.
Daxxify (daxibotulinumtoxinA)
Manufactured by Revance Therapeutics and the most genuinely differentiated entrant in years. Daxxify is stabilized with a proprietary peptide rather than human serum albumin, making it the only major product in the class without an albumin excipient. It is approved for glabellar lines and for cervical dystonia.
Its commercial argument is duration — it is marketed on the claim of longer-lasting results than conventional toxins. Treat that claim with the scrutiny any manufacturer duration claim deserves: real-world duration varies with dose, muscle mass, and patient metabolism, and a longer-lasting result is only an advantage if the patient likes the result. Like its units, it is not interchangeable with Botox.
Letybo (letibotulinumtoxinA)
From South Korean manufacturer Hugel, and the newest FDA-approved arrival in the U.S. glabellar-line market. Letybo is another cosmetic-focused entrant, and it is a signal worth reading: South Korean toxin manufacturers have a large domestic market and a cost structure that makes price competition viable. More entrants from that direction are likely.
Myobloc (rimabotulinumtoxinB)
The category outlier. Myobloc, from Supernus, is a type B toxin rather than type A. It is a therapeutic product — cervical dystonia and sialorrhea — not a cosmetic one, and it is rarely relevant to an aesthetic practice. Its niche use case is patients who have developed resistance to type A products, since the serotypes are immunologically distinct. It has a shorter duration and a different side-effect profile.
Is There a Generic or Biosimilar Botox?
No — and this is the most common misconception in the category.
Botulinum toxin products are biologics, not small-molecule drugs. You cannot synthesize an identical copy the way a generic manufacturer copies a pill. Each product is defined by its own organism strain, purification process, formulation, and potency assay, and the FDA has never approved a botulinum toxin as a generic or a biosimilar to another. That is why the agency mandated distinct generic prefixes — ona-, abo-, inco-, pra-, daxi-, leti- — specifically to prevent clinicians from treating them as substitutes.
The practical consequence is the one that matters most in this whole article: units are brand-specific and never interchangeable. Dysport’s commonly cited conversion ratio to Botox sits somewhere in the 2:1 to 3:1 range depending on indication and source. Drawing up the same number of units of a different brand is a dosing error.
Anything marketed to you as “generic Botox” is either an approved competitor being described sloppily, or it is unapproved product from a grey-market source. The second category is a patient-safety and license-risk problem, not a cost-saving opportunity.
The Competitors That Aren’t Toxins
Focusing only on rival toxin brands understates the competition badly. Botox’s real competitive threat is not Jeuveau taking glabellar share. It is patients spending their aesthetic budget on something else entirely.
Dermal Fillers
Fillers are not substitutes for Botox in a clinical sense — toxins relax muscles to soften dynamic wrinkles, fillers add volume to restore lost structure and address static lines. They solve different problems, and the strongest treatment plans use both.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
But they compete for the same appointment and the same dollar. A patient with a fixed annual budget choosing lip or midface filler is a patient not buying units this quarter. For pricing dynamics in that category, see our filler price guide, and our Complete Dermal Filler Training for the clinical side.
Biostimulators
Poly-L-lactic acid and calcium hydroxylapatite products work by stimulating the patient’s own collagen over months rather than filling immediately. They compete on a different promise — gradual, longer-lasting change rather than a result at two weeks — and they appeal to patients who dislike the maintenance treadmill of quarterly toxin appointments.
Energy-Based Devices
Radiofrequency microneedling, fractional lasers, ultrasound-based tightening, and IPL address skin quality, laxity, texture, and pigment — none of which Botox touches. This is the category with the most durable competitive pull, because it answers patient complaints that no neuromodulator can answer. It is also the highest-capital route into aesthetics. See our Cosmetic Laser Training.
Threads and Topicals
PDO threads compete for the patient who wants lift without surgery. At the other end, prescription-strength topicals and the broader medical skincare market compete for the patient who is not ready for a needle at all — and are the most common first purchase in an aesthetic patient’s lifecycle.
How Practices Actually Choose
In real clinics, brand selection is rarely a purely clinical decision. The factors that decide it:
- Acquisition cost and rebate structure. Manufacturer loyalty and rebate programs are designed to make switching expensive, and they work.
- Patient-facing loyalty programs. Allergan’s consumer rewards ecosystem is one of the strongest retention tools in aesthetic medicine and a real barrier to switching, because patients follow their points.
- Brand recognition. Patients ask for Botox by name. Explaining an alternative costs chair time.
- Storage logistics. Room-temperature storage genuinely matters for smaller or mobile practices.
- Patient allergy profile. Milk protein allergy rules out Dysport. Albumin hypersensitivity rules out most of the class.
- Secondary non-response. A patient who has stopped responding to a type A product may benefit from a lower-protein-load option or, rarely, a type B.
- Supply diversification. Single-supplier dependence is a business risk, and practices that lived through allocation shortages learned it the hard way.
One caution for anyone running the numbers: a lower price per unit does not automatically mean a lower cost per treated area, because units are not comparable across brands. Compare cost per glabellar treatment, not cost per unit. Our guide on building revenue with injectables covers the economics in more depth.
Where the Category Is Heading
Three trends are worth watching, stated as trends and not predictions.
First, cosmetic-only entrants keep arriving, largely from South Korean manufacturers with a cost advantage and no therapeutic pipeline to fund. That pushes downward on price at the low end.
Second, differentiation is shifting from “same thing, cheaper” to actual product attributes — duration, excipient profile, onset. Daxxify’s albumin-free peptide stabilizer is the clearest example.
Third, topical and needle-free delivery of botulinum toxin has been in development for years and would reshape the market if it ever cleared approval at scale. It has not, and it should be described to patients as investigational rather than imminent.
What has not changed: Botox’s therapeutic breadth remains unmatched, and no competitor is close to matching it. For a practice treating migraine, hyperhidrosis, or spasticity as well as wrinkles, the competitive question barely arises.
Frequently Asked Questions
Who are Botox’s main competitors?
In the toxin category: Dysport (Ipsen/Galderma), Xeomin (Merz), Jeuveau (Evolus), Daxxify (Revance), Letybo (Hugel), and the type B product Myobloc (Supernus). Outside the category, dermal fillers, biostimulators, energy-based devices, and threads all compete for the same patient budget.
What are all the Botox brands?
Strictly, “Botox” is one brand — Allergan’s, sold as Botox and Botox Cosmetic. The other names above are separate botulinum toxin brands, not versions of Botox. They share a mechanism, not a formulation or a unit definition.
Who are Allergan’s competitors?
At the company level, Allergan Aesthetics (AbbVie) competes primarily with Galderma, Merz Aesthetics, Evolus, and Revance across toxins and fillers, plus device manufacturers for the broader aesthetic spend.
Is there a Botox biosimilar or generic?
No. Botulinum toxins are biologics, and the FDA has not approved any as a generic or biosimilar to another. Products marketed as “generic Botox” are either approved competitors described inaccurately or unapproved grey-market product.
What is a Botox equivalent?
There is no true equivalent in the substitution sense. The closest functional alternatives for glabellar lines are Dysport, Xeomin, Jeuveau, Daxxify, and Letybo — but each requires brand-specific dosing rather than a one-for-one swap.
What chemical is Botox?
Botulinum toxin type A, a purified protein produced by the bacterium Clostridium botulinum. Every direct competitor except Myobloc uses the same type A serotype. See our guide to what Botox is and how it works.
Is any competitor better than Botox?
“Better” depends on the indication, the patient, and the practice. For therapeutic breadth, nothing comes close to Botox. For storage convenience, Xeomin has an edge. For cosmetic price sensitivity, Jeuveau and Letybo compete hard. Outcomes track injector skill far more closely than they track brand.
Train on the Products — and the Business Behind Them
Every product in this category shares a mechanism. What they do not share is a dose, and none of them produces a good result on their own. Facial anatomy, brand-specific dosing, reconstitution, injection depth, diffusion control, patient selection, and complication management decide the outcome — the vial does not.
Empire Medical Training has trained healthcare professionals in aesthetic medicine since 1998. Our Botox Training & Certification course is CME-accredited and hands-on, with live-patient injection under expert supervision, covering the full neuromodulator class rather than a single brand.
